CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Exogenus Therapeutics is developing therapies using exosomes derived from umbilical cord blood to treat autoimmune diseases. Their approach focuses on harnessing the immunomodulatory properties of these nanosized vesicles to create safer, more effective treatments for over 80 autoimmune conditions affecting millions of…
Exogenus Therapeutics is a drug development company using an exosome-based platform technology to develop an innovative pipeline of therapeutic products.
Exogenus’ scientific team has pioneer research work in the area of Umbilical Cord Blood (UCB)-derived Extracellular Vesicles (EVs) clinical application.
Among EVs, exosomes are nanosized vesicles (30-150nm) released from all types of cells responsible for cell-to-cell communication.
Exogenus’ technology makes use of UCB cells preconditioned in…
EXOGENUS THERAPEUTICS SA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
